Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
REGULATORY
MOF Pushes for Full-Scale FY2027 Off-Year Drug Price Revision Ahead of “Spring” Proposal
Japan’s finance ministry is pressing for the full implementation of the FY2027 off-year drug price revision, arguing that it should be carried out in the same manner as regular biennial revisions without limiting the scope of products or pricing rules.…
To read the full story
Related Article
- MOF Panel Renews Push for Full-Scale Off-Year Revision in FY2027
June 29, 2026
- Japan Ministers Agree to Scrap “Spillover” Rule, Plan Wider CEA Price Cuts
December 25, 2025
- MOF Panel Again Presses for Expansion of CEA Scheme: “Spring” Proposal
May 27, 2025
- MOF’s Spring Debate Puts Special Focus on CEA, More Aggressive Re-Pricing Eyed
April 24, 2025
- MOF Panel Urges Full-Scale Off-Year Revisions, Enhanced CEA: “Spring” Proposal
May 22, 2024
- MOF Ramps Up Push for Use of Cost-Effectiveness Assessment in Reimbursement Decisions
April 17, 2024
REGULATORY
- Pharma Groups Press for Freeze on CEA Price Cuts, Cite Unresolved Issues
September 17, 2026
- Japan Approves Keytruda, Leqembi SC Formulations, Xcopri, and More Drugs
September 17, 2026
- Japan Cabinet Approves Food Tax Cut Outline; 1% Rate for 2 Years
September 16, 2026
- MHLW to Track Prescription Shifts under OTC-Like Drug Charge
September 16, 2026
- CEA Review Has not Settled Debate, LDP Lawmaker Says
September 15, 2026
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…